Table 1.
Induction | Maintenance | Fistulizing | Mucosal healing | Combination | Combination | Rescuea | ||
---|---|---|---|---|---|---|---|---|
thiopurine | methotrexate | |||||||
Anti-TNF alpha | ||||||||
Infliximab | + | + | + | + | + | − | NA | |
Adalimumab | + | + | + | + | +/− | NA | + | |
Certolizumab | + | + | + | # | NA | NA | + | |
Golimumab | NA | NA | NA | NA | NA | NA | NA | |
Anti-integrin | ||||||||
Natalizumab | + | + | NA | NA | NA | NA | NA | |
Vedolizumab | + | + | NA | NA | NA | NA | + | |
Others | ||||||||
Ustekinumab (phase IIb) | + | + | NA | NA | NA | NA | + |
Efficacy of the treatment in patients who have failed previous biologics treatment.
NA: Study is not available.
+: Study is available with a positive outcome.
−: Study is available with a negative outcome.
+/−: Retrospective studies.
#: Study with a positive outcome but not comparing with placebo.